BC-7013: Phase I started
Nabriva began a Phase I trial of topical BC-7013.
Nabriva Therapeutics Forschungs GmbH, Vienna, Austria Product: BC-7013 Business: Infectious Molecular target: NA Description: Pleuromutilin antibiotic agent Indication: Treat bacterial infections Endpoint: Safety Status: Phase...
